
|Articles|October 12, 2019
Prescriber's Guide to Lasmiditan
In October 2019, the FDA approved Eli Lilly's lasmiditan, marketed as Reyvow, for the acute treatment of migraine with or without aura in adults. The drug is the first approved from a new class of serotonin (5-HT)1F receptor agonists. This downloadable PDF serves as a convenient, consolidated prescribing guide to help you incorporate this new migraine therapy into your clinical practice.
Advertisement
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Efgartigimod Effective in Seronegative gMG, Obexelimab Meets Primary End Point, FDA Accepts NDA for Tau Tracer MK-6240
2
Newly Unveiled EPIC Trial Pins Myasthenia Gravis Medications Nipocalimab Against Efgartigimod for Efficacy
3
NeurologyLive® Friday 5 — October 31, 2025
4
Evaluating Combined Supraorbital and Occipital Neuromodulation in Phase 3 Trial for Resistant Migraine: The RECLAIM Study
5































